Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Y-mAbs Therapeutics (YMAB) Tops Q4 EPS by 47c
March 30, 2023 4:04 PM EDTY-mAbs Therapeutics (NASDAQ: YMAB) reported Q4 EPS of $0.03, $0.47 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $31.5 million versus the consensus estimate of $20.35 million.
Financial Guidance
Management reiterated its 2023 financial guidance including:
Anticipated DANYELZA® net product revenues of $60-$65... More